Fig. 1From: An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extensionOverview of study design. DB double-blind; HAE hereditary angioedema, LTP long-term prophylaxis; OLE open-label extension. aFor rollover patients, Day 0 of the open-label extension study coincides with Day 182 of the double-blind studyBack to article page